Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Patent
1987-11-23
1989-03-21
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
424451, 424456, 424457, 424458, 424459, A61K 948, A61K 954
Patent
active
048141755
DESCRIPTION:
BRIEF SUMMARY
The invention relates to nifedipine combination preparations, containing nifedipine with timed release of active agent and a .beta.-blocker, respectively in granulated form, and their pharmeceutical usage as therapeutics in cardiovascular diseases.
German Laid-Open Application DOS No. 3,419,130 describes formulations for nifedipine already pertaining to the state of the art wherein the bioavailability of the sparingly soluble nifedipine has been improved. Possibilities for improving bioavailability are furthermore described by S. H. Yalkowskay in "Drugs and the Pharmaceutical Science", 12: 135 (1981) and by J. Polderman in "Formulation and Preparation of Dosage Forms", 215 (1977), Elsevier, and include grinding of active compound particles, alterations of crystalline structure, addition of wetting agents, or formation of coprecipitates, to name just a few.
European Laid-Open Application EP No. 142,561 claims a nifedipine formulation with release being uniform over a relatively long time period, consisting of a rapidly released composition A and a retarded-release composition B. In both compositions, the nifedipine particles are larger than 5 .mu.m. The slow release of active agent is obtained by coating the nifedipine-containing (such as mono-, di- or triglycerides, hydrogenated oils, and ethylcellulose) and of lacquer materials resistant to gastric acid.
DOS No. 3,318,649 cites a two-phase nifedipine preparation wherein the particle size of the nifedipine used is 1-10 .mu.m, and the nifedipine crystals have a specific surface area of 1.0-4.0 m.sup.2 /g.
The present invention concerns a combination preparation, containing 1 part by weight of nifedipine and 0.05-0.25 part by weight of a .beta.-blocker, and customary auxiliary agents and excipients.
The present invention relates, in particular, to the combination preparation of nifedipine and mepindolol. A preferred combination contains 0.05-0.25 part by weight of mepindolol per 1 part by weight of nifedipine. The particle diameter of the nifedipine employed is 10-50 .mu.m, preferably 15-50 .mu.m. The combinations of this invention are prepared by granulating, in each case separately, mepindolol and nifedipine with conventional auxiliary agents and excipients with the aid of a moist granulation process or dry compacting process; optionally coating the granules with lacquer; and dispensing same into hard gelatin capsules. Suitable auxiliary agents are amylose, modified starch, cellulose, cellulose derivatives, crosslinked polyvinylpyrrolidone (PVPP), sodium alginate and colloidal silicon dioxide, gelatin, glucose syrup, starch mucilage, polyethylene glycol, alginates, magnesium stearate, calcium stearate, stearic acid, paraffin, talc, vegetable or animal fats, oils, and waxes.
Suitable fillers that can be cited are calcium sulfate, calcium carbonate, di- and tribasic calcium phosphates, magnesium carbonate, magnesium hydroxycarbonate, sodium chloride, sodium, potassium and calcium citrates, tartrates and succinates, starch, modified starch, cornstarch, cellulose, cellulose powder, hydroxypropylcellulose, sugars, such as lactose, sucrose or dextrose, and sugar alcohols, such as mannitol or sorbitol.
Further auxiliary agents and excipients used are hydroxypropylmethylcellulose phthalate, cetyl alcohol, ethylcellulose, titanium dioxide, hydrogenated castor oil, polysorbate 80, sodium lauryl sulfate, methacrylic acid copolymer (such as "Eudragit" S 100).
The combined use of nifedipine and mepindolol affords the advantage over conventional preparations that a 24-hour long reduction in blood pressure is achieved even with a reduced dose of nifedipine and mepindolol. The amount of .beta.-blocker used ranges, with 0.05-0.25 part by weight per part by weight of nifedipine, markedly below the amount of 0.5-10 parts by weight of .beta.-blocker per part by weight of nifedipine, disclosed in DOS No. 3,419,130.
EXAMPLES
Example 1
(a) 25 g of mepindolol sulfate is premixed for about 10 minutes with 300 g of calcium citrate and 5 g of magnesium stearate in a "Turbula"
REFERENCES:
patent: 4281654 (1981-08-01), Shell et al.
patent: 4510150 (1985-04-01), Berthold
patent: 4668770 (1987-05-01), Boger
patent: 4690935 (1987-09-01), Taylor et al.
The Merck Index, Tenth Edition "Mepindolol" pp. 835-836, No. 5684 Merck & Co. (1983).
Albring Manfred
Tack Johannes-Wilhelm
Windt-Hanke Fred
Page Thurman K.
Schering Aktiengesellschaft
LandOfFree
Nifedipine combination preparation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nifedipine combination preparation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nifedipine combination preparation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-476075